I don't know if Liver Cancer was one of the solid tumors that were treated back in the solid tumor trial, however, it does appear (based on decreasing TNFR2), that Leronlimab may be effective in treating or at least stopping Liver Cancer
"Liver disease is rapidly becoming one of the major causes of mortality in the Western world, fueled by the growing pandemic of obesity. There is increasing awareness that excessive liver fat (termed steatosis, or non-alcoholic fatty liver—NAFL) is also a precursor to liver inflammation (non-alcoholic steatohepatitis—NASH), fibrosis, and cirrhosis, which are also associated with cardiovascular disease, further contributing to the overall mortality [1–3]. Moreover, NASH and liver fibrosis predispose individuals to hepatocellular carcinoma [4, 5]. Williams et al. showed that the United States prevalence rates of NAFL and NASH were 46% and 12%, respectively [6]. Unfortunately, liver disease is frequently not detected until clinical symptoms appear, when fewer treatment options exist, and many of those with liver disease are unaware of the fact [7]. It is therefore essential to identify those individuals at highest risk of progressing to cirrhosis while the disease is in its early stages."
Hepatocellular carcinoma (HCC): HCC is the most common primary liver cancer. This tumor begins in the liver’s hepatocyte cells. Sometimes HCC begins as a single tumor. Other times, it starts in multiple spots in the liver (multifocal). Multifocal HCC is more common in people with liver inflammation, such as cirrhosis.
"Liver disease is rapidly becoming one of the major causes of mortality in the Western world, fueled by the growing pandemic of obesity. There is increasing awareness that excessive liver fat (termed steatosis, or non-alcoholic fatty liver—NAFL) is also a precursor to liver inflammation (non-alcoholic steatohepatitis—NASH), fibrosis, and cirrhosis, which are also associated with cardiovascular disease, further contributing to the overall mortality [1–3]. Moreover, NASH and liver fibrosis predispose individuals to hepatocellular carcinoma [4, 5]. Williams et al. showed that the United States prevalence rates of NAFL and NASH were 46% and 12%, respectively [6]. Unfortunately, liver disease is frequently not detected until clinical symptoms appear, when fewer treatment options exist, and many of those with liver disease are unaware of the fact [7]. It is therefore essential to identify those individuals at highest risk of progressing to cirrhosis while the disease is in its early stages."
Hepatocellular carcinoma (HCC): HCC is the most common primary liver cancer. This tumor begins in the liver’s hepatocyte cells. Sometimes HCC begins as a single tumor. Other times, it starts in multiple spots in the liver (multifocal). Multifocal HCC is more common in people with liver inflammation, such as cirrhosis.
4
